Accrued Expenses and Other Current Liabilities

3 Months Ended

Mar. 31, 2024

Accrued Liabilities and Other Liabilities [Abstract]

Accrued Expenses and Other Current Liabilities

7.Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consist of the following (in thousands):

	March 31, 2024		December 31, 2023
Marketing reimbursement	$	2,031	$	2,834
Accrued compensation		2,752		1,687
Accrued clinical trials and R&D		4,549		3,694
Accrued selling and marketing		845		1,110
Accrued professional fees		1,152		1,505
Accrued warranty		21		44
Accrued restructuring		8		655
Other accrued expenses		3,148		3,966
Total accrued expenses and other current liabilities	$	14,506	$	15,495

In connection with strategic initiatives implemented during the period ended December 31, 2023, the Company's management approved and initiated plans to reduce its cost structure. During the three months ended March 31, 2024, the Company recorded less than $0.1 million in restructuring charges and paid $0.7 million in restructuring charges.